Table 9.
Indicator | Lighthouse, Lilongwe | Thyolo DH |
Hosseinipour et al86 | ||
References | Neuhann et al87 | Harries et al89 |
Hosseinipour et al88 | ||
Description of cohort | ||
Jan–Jun 2003 (ref 86) | ||
Period | Jul–Dec 2003 (ref 87) | April–Sep 2003 |
Jan–Jul 2003 (ref 88) | ||
179 (ref 86) | ||
Number of patients | 753 (ref 87) | 220 |
141 (ref 88) | ||
WHO stage 3 or 4 | 62% (ref 88) | Not reported |
Women | 52% (ref 88) | Not reported |
CD4 before ART (cells/µl) | 50 (ref 88) | Not reported |
Fee | For medication | Free |
Process | ||
Alive and on ARV | 64% at 6 months (ref 88) | 90% after 3–6 months |
Lost to follow-up | 7% at 6 months(ref 88) | 0% after 3–6 months |
Stopped therapy | 3% at 6 months (ref 88) | 4% after 3–6 months |
On alternative 1st line therapy | 1% (ref 88) | 4% |
On 2nd line therapy | 0% (ref 88) | 0% |
Adherent ≥ 95% | 95% (ref 88) | 99% |
Outcome | ||
Median change in bodyweight (kg) | 5.7 (ref 88) | Not reported |
Median change in CD4 count (cells/µl) | 92 (ref 88) | Not reported |
HIV RNA below 400 copies | 79% (ref 88) | Not reported |
Resumed normal daily activity | 72% (ref 87) | 88% |
Early mortality (≤3 months) | 25% (ref 86) | Not reported |
Total mortality | 27% (ref 88) | 6% |
Side effects reported | 32% (ref 87)* | 14% |
Study only reported on neuropathic pain